Please assess the completion status of the following clinical trial:

Trial Title: Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject with a confirmed clinical diagnosis of a Primary Humoral Immunodeficiency Disease as defined by IUIS (International Union of Immunological Societies) and require treatment with IGIV. Documented agammaglobulinemia or hypogammaglobulinemia~* Male or Female, ages 2 to 70 years~* The subject has received 300-900 mg/kg of a licensed IGIV therapy at 21 or 28 day intervals for at least 3 months prior to this study~* At least 2 documented IgG trough levels of ≥ 500 mg/dL are obtained at two infusion cycles (21 or 28 days) within 12 months prior to study enrollment~Exclusion Criteria:~* Subject has secondary immunodeficiency~* Subject was newly diagnosed with PHID and has not yet been treated with immunoglobulin~* Subject has been diagnosed with dysgammaglobulinemia or isolated IgG subclass deficiency or isolated IgA deficiency with known anti-IgA antibodies~* History of severe reaction or hypersensitivity to IGIV or other injectable form of IgG~* Subject has a lifetime history of at least one thrombotic event including deep vein thrombosis, cerebrovascular accident, pulmonary embolism, transient ischemic attacks, or myocardial infarction~* Subject has received blood products other than human albumin or human immunoglobulin within 12 months prior to enrollment

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- GC5107 (Type: EXPERIMENTAL): GC5107 Immune globulin intravenous (human) solution, 10% liquid

Based on this trial design, predict the completion outcome and termination type (if applicable).